APPLIED GENETIC TECHNOLOGIES CORP·4

Dec 1, 9:14 AM ET

Washer Susan B. 4

4 · APPLIED GENETIC TECHNOLOGIES CORP · Filed Dec 1, 2022

Insider Transaction Report

Form 4
Period: 2022-11-30
Washer Susan B.
DirectorPresident & CEO
Transactions
  • Disposition from Tender

    Common Stock

    2022-11-30143,0210 total
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2022-11-3080,0000 total
    Exercise: $15.57Exp: 2026-07-07Common Stock (80,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2022-11-30100,0000 total
    Exercise: $3.00Exp: 2029-08-15Common Stock (100,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2022-11-30442,0000 total
    Exercise: $0.40Exp: 2032-08-21Common Stock (442,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2022-11-30169,0000 total
    Exercise: $5.50Exp: 2030-08-05Common Stock (169,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2022-11-3099,1560 total
    Exercise: $14.08Exp: 2024-04-17Common Stock (99,156 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2022-11-3080,0000 total
    Exercise: $18.48Exp: 2025-07-21Common Stock (80,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2022-11-30140,0000 total
    Exercise: $4.90Exp: 2023-09-18Common Stock (140,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2022-11-30100,0000 total
    Exercise: $4.25Exp: 2028-07-25Common Stock (100,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2022-11-3055,7800 total
    Exercise: $16.00Exp: 2024-07-31Common Stock (55,780 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2022-11-30100,0000 total
    Exercise: $4.90Exp: 2027-07-17Common Stock (100,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2022-11-30275,0000 total
    Exercise: $3.74Exp: 2031-07-27Common Stock (275,000 underlying)
Footnotes (2)
  • [F1]At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for (1) $0.34 per share of common stock of the Issuer ("Common Stock"), without interest and less any applicable withholding taxes (the "Cash Consideration"); and (2) one contingent value right ("CVR") per share of Common Stock representing the right to receive potential milestone payments, currently estimated to be up to approximately $0.73 per CVR in the aggregate (without interest and less any applicable withholding taxes) (the Cash Consideration plus one CVR, collectively, as such amount may be increased in accordance with the terms of the Merger Agreement, the "Offer Price"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Offer Price.
  • [F2]At the effective time of the Merger, each outstanding option of the Issuer with an exercise price equal to or greater than $0.34 was cancelled without any consideration in respect of such cancelled option.

Documents

1 file
  • 4
    form4.xmlPrimary

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES